[Research progress of negative costimulator B7-H4 in urologic tumors]

Yan Tao; Mei Hong

doi:10.3785/j.issn.1008-9292.2014.06.006

[Research progress of negative costimulator B7-H4 in urologic tumors]

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2014 Jul;43(4):480-5. doi: 10.3785/j.issn.1008-9292.2014.06.006.

[Article in Chinese]

Authors

Yan Tao¹, Mei Hong¹

Affiliation

¹ Institute of Urology, Second Hospital of Lanzhou University, Gansu Provincial Key Laboratory of Urological Diseases, Gansu Nephro-Urological Clinical Center, Lanzhou 730030, China.

PMID: 25187465
DOI: 10.3785/j.issn.1008-9292.2014.06.006

Abstract

B7-H4 is a recently-identified member of B7 costimulation superfamily. B7-H4 serves as an inhibitory modulator of T cell response through suppressing the proliferation, activation, and cytokine production of T cells. B7-H4 is found to be abnormally expressed in multiple human tumors. Many studies have shown that B7-H4 expression is closely related to the progression and prognosis of urologic tumors. Investigation of B7-H4 function will provide new strategies for diagnosis and immunotherapy of urologic tumors. This article reviews the recent progress of B7-H4 research in urologic tumors.

Publication types

English Abstract
Research Support, Non-U.S. Gov't
Review

MeSH terms

Humans
Interleukin-2
Urologic Neoplasms*
V-Set Domain-Containing T-Cell Activation Inhibitor 1*

Substances

Interleukin-2
V-Set Domain-Containing T-Cell Activation Inhibitor 1